Triphenylphosphine-docetaxel conjugate-incorporated albumin nanoparticles for cancer treatment
- Authors
- Battogtokh, Gantumur; Gotov, Oyuntuya; Kang, Jee He; Cho, Jinsung; Jeong, Tae Ho; Chimed, Ganzorig; Ko, Young Tag
- Issue Date
- Feb-2018
- Publisher
- FUTURE MEDICINE LTD
- Keywords
- anticancer drug; docetaxel; mitochondria targeting; self-assembled albumin nanoparticle; triphenylphosphonium cation
- Citation
- NANOMEDICINE, v.13, no.3, pp.325 - 338
- Journal Title
- NANOMEDICINE
- Volume
- 13
- Number
- 3
- Start Page
- 325
- End Page
- 338
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/4098
- DOI
- 10.2217/nnm-2017-0274
- ISSN
- 1743-5889
- Abstract
- Aim: The objective of this study was to develop a mitochondria-targeted anticancer drug, docetaxel (DTX), for chemotherapy. Materials & methods: The DTX was conjugated to 4-carboxybutyl triphenylphosphonium (TPP) to enhance mitochondrial targeting, and the TPP-DTX conjugate was further loaded into folate-cholesteryl albumin (FA-chol-BSA) nanoparticles (NPs) to improve its biocompatibility. Results & conclusion: In vitro studies showed that TPP-DTX and its NP primarily accumulated in the mitochondria; generated high reactive oxygen species, leading to mitochondrial disruption and cell apoptosis; and had a higher cytotoxicity against cancer cells. In vivo antitumor studies indicated that the NP significantly suppressed tumor growth compared with free drugs in xenograft tumor-bearing mice. Our results demonstrated that TPP-DTX@FA-chol-BSA NPs could be a promising mitochondria-targeted anticancer prodrug for chemotherapy.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 약학대학 > 약학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/4098)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.